{"title":"筛选 Kabasura Kudineer 对 COVID 19 和人体免疫蛋白的有效性：硅学","authors":"Architha Vijayalakshmi, Hemalatha S","doi":"10.2174/0126667975281429231206073959","DOIUrl":null,"url":null,"abstract":"\n\nThe advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first\ncentury. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has\ngreatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants.\nHowever, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and\ntheir side effects.\n\n\n\nThe main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against\nCOVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans\n\n\n\nThe molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check\nthe Pharmacokinetics.\n\n\n\nThe results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.\n\n\n\nSiddha way of treatment has popped out which has been traditionally used for the\ntreatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven\nto have antiviral agents and compounds that boost the immune system\n","PeriodicalId":10815,"journal":{"name":"Coronaviruses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Screening the Effectiveness of Kabasura Kudineer against COVID 19 and\\nImmune Proteins in Humans: In silico\",\"authors\":\"Architha Vijayalakshmi, Hemalatha S\",\"doi\":\"10.2174/0126667975281429231206073959\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nThe advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first\\ncentury. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has\\ngreatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants.\\nHowever, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and\\ntheir side effects.\\n\\n\\n\\nThe main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against\\nCOVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans\\n\\n\\n\\nThe molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check\\nthe Pharmacokinetics.\\n\\n\\n\\nThe results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.\\n\\n\\n\\nSiddha way of treatment has popped out which has been traditionally used for the\\ntreatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven\\nto have antiviral agents and compounds that boost the immune system\\n\",\"PeriodicalId\":10815,\"journal\":{\"name\":\"Coronaviruses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Coronaviruses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0126667975281429231206073959\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronaviruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126667975281429231206073959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Screening the Effectiveness of Kabasura Kudineer against COVID 19 and
Immune Proteins in Humans: In silico
The advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first
century. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has
greatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants.
However, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and
their side effects.
The main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against
COVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans
The molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check
the Pharmacokinetics.
The results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.
Siddha way of treatment has popped out which has been traditionally used for the
treatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven
to have antiviral agents and compounds that boost the immune system
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
